Nurix Therapeutics Inc reports results for the quarter ended in November - Earnings Summary

Nurix Therapeutics

09/02/2023 23:55

* Nurix Therapeutics Inc  NRIX.OQ  reported a quarterly
adjusted
loss of 87 cents​​ per share for the quarter ended in November.
The mean expectation of nine analysts for the quarter was for a
loss of 79 cents per share.
    * Revenue fell 8.3% to $6.78 million from a year ago;
analysts
expected $17.17 million. 
    * Nurix Therapeutics Inc's reported EPS for the quarter was
a loss
of 87 cents​.
    * The mean earnings estimate of analysts had risen by
about 0.7%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Nurix Therapeutics Inc shares had risen by 5.1% this
quarter.
    * The company reported a quarterly loss of $46.72 million.
    * Wall Street's median 12-month price target for Nurix
Therapeutics Inc is $35.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data February
9 at 11:55 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Nov. 30 2022      -0.79          -0.87          Missed
 Aug. 31 2022      -0.98          -0.90          Beat
 May. 31 2022      -0.99          -1.01          Missed
 Feb. 28 2022      -0.88          -0.95          Missed